News
University student develops cooling device for hot flushes
The product uses thermoelectric technology to create a cold sensation and provide instant hot flush relief
A London-based university student has developed a menopause cooling device to help women manage hot flushes.
The device, called the Zera Cooling Crescent, has been designed by Brunel University London student Aphra Hallam who wanted to develop a portable, discreet and diverse wearable that could easily fit inside a handbag and allow women to use it on the go.
The product sticks to the back of the neck and uses thermoelectric technology to create a cold sensation and provide instant hot flush relief. Controlled via Bluetooth by an app, the device comes in different skin-coloured tones and can be easily used throughout the day.
Hot flushes, a common symptom of the menopause, feel like a sudden flare of heat, paired with sweating and flushed skin. Although the frequency and intensity vary, some women find that they can often interrupt their daily lives.
There can be different patterns of when women first experience hot flushes and for how long. However, multiple studies have shown that black and hispanic women are more likely to experience hot flushes for more years than white and Asian women.
“Symptoms [in black women] can last up to a decade, due to a mix of environmental factors and genetics,” said 22-year old Hallam.
“As a black woman, I was inspired to create the product to help empower women and reduce the stigma of ageing while being sensitive to the racial disparities in reproductive ageing.”
Hallam was inspired to create Zera after seeing her mother struggling with hot flushes.
“She’s into natural products, and there weren’t many natural remedies available for hot flushes,” she explained.

Aphra Hallam/ Source: Brunel University London
“The wrist and neck are the two main points on the body that cool you down quickest, and the other cooling products I saw were similar to bracelets to wear around the wrist.
“My mum isn’t really into wrist jewellery, which is why I wanted to create a cooling device for the neck. Hair and clothes can also be used to cover it up, making it more discreet.”
She added: “The size was also important. The Zera Cooling Crescent is charged in a small case that can be easily carried around.
“When activated by the Zera app, the device produces a cooling sensation that targets the blood vessels in the back of the neck. Its close proximity to the end of the brain stem allows your body to cool down.
“The app also provides additional support and tracking for other menopause symptoms and has a community feature that provides [users with] a support system.”
Hallam hopes the product will become a viable solution for women experiencing hot flushes.
“The menopause is not as widely talked about as it should be, even though it affects such a large proportion of the population. I hope that Zera raises awareness about menopausal symptoms and addresses racial disparities,” she said.
“The Cooling Crescent can be used on the go and will provide a quick and easy solution.”
The Zera Cooling Crescent device was unveiled at the annual Made in Brunel exhibition, which showcased gadgets and devices designed by final-year students from Brunel Design School.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






